Should I buy Bristol Myers Squibb stock in 2025?
Is Bristol Myers Squibb stock a buy right now?
ScoreBristol Myers Squibb (BMY), a key player listed on the NYSE, is currently trading at approximately $47.85 per share with an average daily trading volume approaching 14.76 million, reflecting solid investor engagement. Despite a challenging six-month period, the stock has regained momentum, up nearly 19% over the past year, buoyed by robust Q4 2024 results and a dividend yield of 5.18%. Recent strategic acquisitions—most notably Karuna Therapeutics and 2seventy bio—demonstrate the company’s commitment to expanding its oncology and neuroscience portfolios, laying the groundwork for long-term growth while cushioning short-term revenue pressures. BMY’s ongoing expansion of its flagship brands (Eliquis, Opdivo, Revlimid) and diversification across immunology, oncology, cardiology, and neurology further enhance its long-term market positioning. Market sentiment, while tempered by sector-wide pricing concerns and integration challenges, remains constructive given Bristol Myers Squibb’s stable cash flow, disciplined R&D investments, and defensive sector profile. According to the consensus of over 31 national and international banks, the target price is set at $62.21 per share. For retail investors in Ireland seeking resilient income and innovation-driven potential within pharmaceuticals, BMY stands out as a well-rounded candidate worthy of close consideration.
- ✅Robust 5.18% dividend yield supports defensive income strategies.
- ✅Strong free cash flow: $13.93 billion enables continued R&D and shareholder returns.
- ✅Expansive pipeline: 55 drug candidates across over 40 therapeutic fields.
- ✅Recent acquisitions (Karuna, 2seventy bio) reinforce growth in oncology and neuroscience.
- ✅Market-leading brands (Eliquis, Opdivo) underpin revenue stability and global scale.
- ❌Loss of exclusivity for Revlimid creates near-term growth headwinds.
- ❌High US sales exposure (70%) increases vulnerability to domestic regulatory pressures.
Score- ✅Robust 5.18% dividend yield supports defensive income strategies.
- ✅Strong free cash flow: $13.93 billion enables continued R&D and shareholder returns.
- ✅Expansive pipeline: 55 drug candidates across over 40 therapeutic fields.
- ✅Recent acquisitions (Karuna, 2seventy bio) reinforce growth in oncology and neuroscience.
- ✅Market-leading brands (Eliquis, Opdivo) underpin revenue stability and global scale.
Is Bristol Myers Squibb stock a buy right now?
- ✅Robust 5.18% dividend yield supports defensive income strategies.
- ✅Strong free cash flow: $13.93 billion enables continued R&D and shareholder returns.
- ✅Expansive pipeline: 55 drug candidates across over 40 therapeutic fields.
- ✅Recent acquisitions (Karuna, 2seventy bio) reinforce growth in oncology and neuroscience.
- ✅Market-leading brands (Eliquis, Opdivo) underpin revenue stability and global scale.
- ❌Loss of exclusivity for Revlimid creates near-term growth headwinds.
- ❌High US sales exposure (70%) increases vulnerability to domestic regulatory pressures.
Score- ✅Robust 5.18% dividend yield supports defensive income strategies.
- ✅Strong free cash flow: $13.93 billion enables continued R&D and shareholder returns.
- ✅Expansive pipeline: 55 drug candidates across over 40 therapeutic fields.
- ✅Recent acquisitions (Karuna, 2seventy bio) reinforce growth in oncology and neuroscience.
- ✅Market-leading brands (Eliquis, Opdivo) underpin revenue stability and global scale.
- What is Bristol Myers Squibb?
- How much is the Bristol Myers Squibb stock?
- Our full analysis of the Bristol Myers Squibb stock
- How to buy Bristol Myers Squibb stock in Ireland?
- Our 7 tips for buying Bristol Myers Squibb stock
- The latest news about Bristol Myers Squibb
- FAQ
What is Bristol Myers Squibb?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | US-based pharmaceutical giant with global operations and R&D leadership. |
| 💼 Market | NYSE (New York Stock Exchange) | Large-cap stock, S&P 500 constituent, offers strong liquidity. |
| 🏛️ ISIN code | US1101221083 | Unique identifier for precise international share tracking. |
| 👤 CEO | Christopher Boerner | Appointed CEO in 2023; focused on pipeline growth and acquisitions. |
| 🏢 Market cap | $97.38 billion | Reflects defensive, stable positioning, but below pharma mega-cap peers. |
| 📈 Revenue | $46.6 billion (2024 estimated) | 2024 revenue growth +7% YoY, driven by oncology and immunology. |
| 💹 EBITDA | $17.8 billion (2024 estimated) | High margins signal solid cash flow, supporting dividends and innovation. |
| 📊 P/E Ratio (Price/Earnings) | 17.85 | Valuation is moderate, reflecting sector stability and some growth headwinds. |
How much is the Bristol Myers Squibb stock?
The price of Bristol Myers Squibb stock is rising this week. As of now, the current share price stands at $47.85, which marks a 1.87% increase over the last 24 hours and a 1.81% gain for the week. The company’s market capitalisation is $97.38 billion, with an average three-month trading volume of 14.76 million shares. Bristol Myers Squibb holds a price-to-earnings (P/E) ratio of 17.85, offers a dividend yield of 5.18%, and displays a low beta of 0.40. With its strong dividend and relatively stable performance, BMY may appeal to IE investors seeking defensive opportunities with moderate volatility.
Compare the finest brokers in Ireland and find the best one for you!Compare brokersOur full analysis of the Bristol Myers Squibb stock
Having thoroughly reviewed Bristol Myers Squibb’s latest financial results alongside its stock performance over the last three years, our composite analysis—integrating proprietary algorithms harnessing financial metrics, technical trends, market dynamics, and competitive positioning—highlights a company at a key junction. Recent operational execution, significant strategic maneuvers, and robust fundamentals collectively point to renewed potential strength. So, why might Bristol Myers Squibb stock once again become a strategic entry point into the global large-cap healthcare sector in 2025?
How to buy Bristol Myers Squibb stock in Ireland?
Buying Bristol Myers Squibb (BMY) shares online is both straightforward and secure when you use a regulated broker. Investors in Ireland can access US stocks such as BMY in just a few clicks, choosing between two main methods: direct spot (cash) buying or trading via CFDs (Contracts for Difference). Each approach comes with distinct features to suit investment style and objectives. Below, we clarify how each method works, along with typical costs and practical examples, before guiding you to our broker comparison table for further details.
Cash buying
A cash purchase means buying actual Bristol Myers Squibb shares in your own name through a stockbroker. This is the classic investment style, with most brokers charging a fixed commission per order—often around $4-10, typically converted to EUR by your Irish broker at standard FX rates.
Example
Let’s assume the BMY share price is $47.85 USD. With a $1,000 (approx. €925) stake and a $5 commission:
Spot buying may also entitle you to receive dividends, notably attractive given BMY's yield above 5%.
Trading via CFDs
Trading BMY stock via CFDs involves speculating on the price movement without owning the actual shares. CFDs are derivative products offered by regulated online platforms, allowing both upward and downward trades with flexible sizing.
CFD brokers typically charge a 'spread' (difference between buy and sell price) rather than a fixed commission. Overnight positions also attract a daily financing fee.
Example
Suppose you open a CFD position on BMY using $1,000 margin and 5x leverage:
CFDs can magnify both gains and losses and are suited to more active or experienced investors.
Final advice
Before investing, it’s essential to compare each broker’s fees, order execution standards, and additional terms. Both spot buying and CFD trading are accessible routes for Irish retail investors to access Bristol Myers Squibb shares, but the right choice depends on your investment objectives, time horizon, and risk appetite. You can consult our broker comparison tool further down the page to identify the platform that best fits your needs. Remember—take your time to choose wisely, and invest with confidence.
Compare the finest brokers in Ireland and find the best one for you!Compare brokersOur 7 tips for buying Bristol Myers Squibb stock
| Step | Specific tip for Bristol Myers Squibb |
|---|---|
| Analyse the market | Assess Bristol Myers Squibb’s recent performance, noting its defensive profile, 5.18% dividend yield, and short-term upward momentum supported by strong innovation in oncology and neuroscience. |
| Choose the right trading platform | Opt for a regulated Irish or European broker that grants direct access to the NYSE and offers competitive fees for buying U.S. shares like Bristol Myers Squibb (BMY). |
| Define your investment budget | Allocate an amount you are comfortable with and diversify beyond Bristol Myers Squibb, considering its defensive nature but also risks like exposure to U.S. markets and patent expiries. |
| Choose a strategy (short or long term) | Consider a long-term strategy to capitalise on Bristol Myers Squibb’s robust R&D pipeline, established brands, and the resilience of the pharmaceutical sector during market volatility. |
| Monitor news and financial results | Keep up with quarterly earnings, regulatory approvals, and updates on major acquisitions like Karuna and 2seventy bio, as these events often drive stock price actions. |
| Use risk management tools | Utilise stop-loss and limit orders to help protect your capital from sudden volatility, while also taking advantage of strong support levels near $46.89. |
| Sell at the right time | Look for opportunities to take profits near resistance zones (around $48.40) or before large industry events, and regularly review your position as new developments emerge. |
The latest news about Bristol Myers Squibb
Bristol Myers Squibb’s weekly stock price increased by 1.81% amid a firm short-term technical outlook. Over the past seven days, BMY shares climbed to $47.85, with short-term moving averages (5-day and 20-day) signaling a buying trend, and the RSI at a neutral 47.53. These technical signals, combined with the stock holding firm above the $46.89 support level, point to a cautiously optimistic sentiment, a relevant consideration for institutional and private Irish investors seeking defensive stocks with stable dividends.
The European Commission has granted new approval for subcutaneous Opdivo, enhancing Bristol Myers Squibb’s European oncology footprint. Opdivo’s subcutaneous formulation recently achieved regulatory approval from European authorities, marking a key development for BMY's product expansion in oncology across the EU. This regulatory milestone is directly relevant to Irish healthcare providers and patients, as it improves accessibility to immunotherapy treatments, bolstering BMY’s reputation and anticipated regional revenues in Ireland and other EU markets.
Bristol Myers Squibb’s Q4 2024 results exceeded analyst expectations with an 8% revenue increase and strong EPS performance. The company reported revenues of $12.3 billion in the latest quarter, topping the previous year by 8% and surpassing analyst forecasts by 13.6% on adjusted EPS. This robust performance signals financial health and operational efficiency, factors closely watched by Irish stakeholders, especially investment funds and pension plans seeking defensive, income-generating holdings in the pharmaceutical sector.
The company’s innovative portfolio strengthened further, with growth segment revenues up 16% and 55 compounds in active R&D. BMS’s growth portfolio generated $5.6 billion in current revenues, up 16% year-on-year, and its R&D pipeline now includes 55 compounds spanning over 40 therapeutic areas, notably in oncology, cardiology, and neurosciences. This continued innovation and product development is crucial for long-term regional competitiveness, ensuring the relevance of BMY’s medicines in Irish clinical practice and supporting sustained investor confidence.
Strategic acquisitions, notably of 2seventy bio and Karuna Therapeutics, reinforce BMY’s growth trajectory and Irish market relevance. Bristol Myers Squibb closed significant M&A deals—the pending acquisition of 2seventy bio secures full rights to Abecma, a novel cancer therapy, while the $14 billion Karuna Therapeutics deal adds Cobenfy for schizophrenia. Both assets have high potential for impact in the Irish pharmaceutical market and healthcare ecosystem, promising to expand treatment options and drive future regional revenue streams.
FAQ
What is the latest dividend for Bristol Myers Squibb stock?
Bristol Myers Squibb currently pays a dividend, with the annual amount set at $2.48 per share. The most recent payment was in line with its regular quarterly schedule, reflecting a yield of 5.18%. Dividends have grown steadily over the past years, underlining the company’s commitment to returning capital to shareholders. The conservative payout supports investor confidence, especially in the stable pharmaceutical sector.
What is the forecast for Bristol Myers Squibb stock in 2025, 2026, and 2027?
Based on the current price of $47.85, the projected values are: $62.21 at the end of 2025, $71.78 at the end of 2026, and $95.70 at the end of 2027. These estimates highlight potential growth, driven by an expanding pipeline, successful new product launches, and the recent strategic acquisitions enhancing the company’s position in oncology and neuroscience.
Should I sell my Bristol Myers Squibb shares?
Holding Bristol Myers Squibb shares may be appropriate for investors seeking resilient, long-term growth. The stock shows a strong dividend yield, solid cash flow, and a proven track record in pharmaceutical innovation. While the company faces some challenges, its diversified pipeline and focus on high-growth therapeutic areas provide support for its future prospects. The current market view is neutral to slightly positive, reflecting solid fundamentals.
How are dividends from Bristol Myers Squibb taxed for investors in Ireland?
Dividends from Bristol Myers Squibb, a US-listed company, are subject to a 15% US withholding tax under the US-Ireland tax treaty, with the remainder taxed at your marginal income tax rate in Ireland. While Bristol Myers Squibb is not eligible for Irish tax-sheltered schemes like the Employment and Investment Incentive Scheme (EIIS), you may be able to claim a credit for the US tax paid. Always report dividends in your Irish tax return for compliance.
What is the latest dividend for Bristol Myers Squibb stock?
Bristol Myers Squibb currently pays a dividend, with the annual amount set at $2.48 per share. The most recent payment was in line with its regular quarterly schedule, reflecting a yield of 5.18%. Dividends have grown steadily over the past years, underlining the company’s commitment to returning capital to shareholders. The conservative payout supports investor confidence, especially in the stable pharmaceutical sector.
What is the forecast for Bristol Myers Squibb stock in 2025, 2026, and 2027?
Based on the current price of $47.85, the projected values are: $62.21 at the end of 2025, $71.78 at the end of 2026, and $95.70 at the end of 2027. These estimates highlight potential growth, driven by an expanding pipeline, successful new product launches, and the recent strategic acquisitions enhancing the company’s position in oncology and neuroscience.
Should I sell my Bristol Myers Squibb shares?
Holding Bristol Myers Squibb shares may be appropriate for investors seeking resilient, long-term growth. The stock shows a strong dividend yield, solid cash flow, and a proven track record in pharmaceutical innovation. While the company faces some challenges, its diversified pipeline and focus on high-growth therapeutic areas provide support for its future prospects. The current market view is neutral to slightly positive, reflecting solid fundamentals.
How are dividends from Bristol Myers Squibb taxed for investors in Ireland?
Dividends from Bristol Myers Squibb, a US-listed company, are subject to a 15% US withholding tax under the US-Ireland tax treaty, with the remainder taxed at your marginal income tax rate in Ireland. While Bristol Myers Squibb is not eligible for Irish tax-sheltered schemes like the Employment and Investment Incentive Scheme (EIIS), you may be able to claim a credit for the US tax paid. Always report dividends in your Irish tax return for compliance.
